Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

XORTX Therapeutics Inc V.XRTX

Alternate Symbol(s):  XRTX

XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.


TSXV:XRTX - Post by User

Comment by KOkidneydiseaseon Aug 16, 2021 8:10am
96 Views
Post# 33708753

RE:RE:RE:RE:RE:CEO, Allen STOP RollBack, Do Not Commit a SEC-USA investigat

RE:RE:RE:RE:RE:CEO, Allen STOP RollBack, Do Not Commit a SEC-USA investigatHOLD ON TO YOUR PANTIES GIRLS

Share price required is $4 so a rollback of 45 to 1?? I'm buying your shares. Put them up.

Roll back likely in the 5-10 range meaning 1 to 5 up to 1-10 rollback. At todays close we only need a 1-10 for a $4.20. Under some circumstances we can even get by with a $2 to $3 share price, so even with the last close a 1for 5 is possible.

The consolidation is required to get listed on the NASDAQ. Combine the roll back with a financing and NASDAQ listing that also requires 3 market makers to sponsor XORTX all means we will see a probale price appreciation!!


all roll backs are not the same.
<< Previous
Bullboard Posts
Next >>